MarginsXMarginsX
Home › Markets › Health Care › VYGR

Voyager Therapeutics Inc. (VYGR)

VYGR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.63
-5.78% on the day
Market cap
$101.4M
Micro cap
Revenue · 2025
$40.4M
-49.5% on 2024
Net income · 2025
-$119.7M
-296.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1640266/000110465926025197/0001104659-26-025197-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVYGR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2015
SEC CIK0001640266
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$40.4M
Net income-$119.7M
Operating income-$131.8M
Net margin-296.5%
Operating margin-326.6%
Revenue growth-49.5%
Cash$65.3M
Total assets$252.3M
P/E (computed)Net income was not positive
P/S (computed)2.5×

Warning signs

Cash runway
5.3 months
$48.4M cash at September 30, 2026
Share count, 1 year
+11.9%
2025-11-03 to 2026-10-30 · +41.4% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$335K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$48.4M cash; operating cash flow -$27.3M a quarter.Report 2026-09-30
Shares outstanding62,229,182 (2026-10-30); 55,600,084 a year earlier; 43,995,363 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $335K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$4.0M-$24.7M-$19.7M$48.4MNo debt tags$25.1M10-Q 2026-11-05
Q2 2026
2026-06-30
$3.2M-$24.5M-$25.8M$35.8MNo debt tags$34.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$2.6M-$27.9M-$33.4M$43.3MNo debt tags$36.5M10-Q 2026-05-07
Q4 2025
2025-12-31
$15.3M-$27.4M-$30.3M$65.3MNo debt tags$40.4M10-K 2026-03-09
Q3 2025
2025-09-30
$13.4M-$27.9M-$31.0M$45.1MNo debt tags$31.3M10-Q 2026-11-05
Q2 2025
2025-06-30
$5.2M-$33.4M-$33.3M$43.9MNo debt tags$42.6M10-Q 2026-08-06
Q1 2025
2025-03-31
$6.5M-$31.0M-$37.9M$74.8MNo debt tags$67.0M10-Q 2026-05-07
Q4 2024
2024-12-31
$6.3M-$34.5M-$14.5M$71.4MNo debt tags$80.0M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-12-01
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 685 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.5%
1 month-19.5%
3 months-46.3%
Year to date-56.0%
1 year-56.5%
From 52-week high-65.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
MOLNMolecular Partners AG$2.70-8.21%$101.2M
ZURAZura Bio Limited$1.08-12.90%$104.0M
OTLKOutlook Therapeutics Inc.$0.3960-4.12%$96.4M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M
BDTXBlack Diamond Therapeutics Inc.$1.53+4.08%$87.9M
CMPXCompass Therapeutics Inc.$0.6615-14.51%$119.1M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier